PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
An independent Data and Safety Monitoring Board recommended advancing PepGen's Phase 2 FREEDOM2-DM1 study into the highest planned dose cohort of 12.5 mg/kg with no protocol changes. PGN-EDODM1 remains well-tolerated with no serious adverse events or dose-limiting toxicities, prompting a dose escalation in the open-label extension study to 10 mg/kg.
Key figures
- Drug Name
- PGN-EDODM1
- Phase Of Trial
- Phase 2
- Ole dose mg kg
- 10
- Highest dose mg kg
- 12.5
- Ole enrollment total
- 16
- Ole enrollment from 5mg cohort
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.